News

NIH maps indoor allergens prevelance nationwide

BY Michael Johnsen

Allergens are widespread, but highly variable in U.S. homes, according to the nation’s largest indoor allergen study to date. Researchers from the National Institutes of Health on Thursday reported that more than 90% of homes had three or more detectable allergens, and 73% of homes had at least one allergen at elevated levels.

“Elevated allergen levels can exacerbate symptoms in people who suffer from asthma and allergies, so it is crucial to understand the factors that contribute,” stated Darryl Zeldin, senior author and scientific director at the National Institute of Environmental Health Sciences, which is part of NIH.

Using data from the 2005-2006 National Health and Nutrition Examination Survey (NHANES), the researchers studied levels of eight common allergens – cat, dog, cockroach, mouse, rat, mold, and two types of dust mite allergens – in the bedrooms of nearly 7,000 U.S. homes.

They found that the presence of pets and pests had a major influence on high levels of indoor allergens. Housing characteristics also mattered – elevated exposure to multiple allergens was more likely in mobile homes, older homes, rental homes, and homes in rural areas.

The findings were published November 30 in the Journal of Allergy and Clinical Immunology.

For individual allergens, exposure levels varied greatly with age, sex, race, ethnicity and socioeconomic status. Differences were also found between geographic locations and climatic conditions. For example, elevated dust mite allergen levels were more common in the South and Northeast, and in regions with a humid climate. Levels of cat and dust mite allergens were also found to be higher in rural areas than in urban settings.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Tena improves incontinence line with new breathable technology

BY Michael Johnsen

Philadelphia-based Tena on Thursday announced its Premium Briefs, Protective Underwear and Heavy Pad incontinence products will now feature Tena ConfioAir 100% breathable technology, which allows excess moisture to evaporate, to help maintain skin's natural moisture balance and improve comfort for wearers.

"We look beyond the product to focus on the individuals, and are dedicated to finding new solutions that offer optimum fit and functionality while improving quality of care," stated Jessica Lan, director product management for Essity Health and Medical Solutions, North America, which manufactures the products. "With this upgrade to our absorbent line, we are pleased to provide more options that help maintain a care routine and lead to better skin health."

"Tena ConfioAir 100% breathable technology is unlike any other innovation in the field of adult incontinence," noted Tony Forsberg, national clinical director for Essity Health and Medical Solutions, North America. "While almost every other product has breathable materials from the front to back of the brief, with ConfioAir we can now keep moisture away from the skin and protect it with a whole vapor- and heat- permeable product."

Tena's ConfioAir technology features a unique outer layer with micro-pores that allows moisture from the inner absorbent core to evaporate. This helps maintain skin's natural moisture balance, allowing it to breathe and keeping the skin on the inside of the product comfortable and dry. This technology is now included across Tena's premium absorbent product line at no additional cost to the customer.

For the large population that suffers from incontinence, discomfort can happen quickly. Many incontinent individuals are elderly and have fragile skin that faces a variety of threats including skin ulcers, incontinence-associated dermatitis and infection as well as greater potential for injury as healing slows down. Recognizing that skin health is important for incontinent individuals, who are at risk of painful irritations from prolonged exposure to moisture, it is vital to provide comfort and care to the perineal area and support the overall quality of life for product users.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Innovus launches low-cost nasal spray allergy relief in FlutiCare

BY Michael Johnsen

Earlier this month Innovus Pharmaceuticals launched FlutiCare OTC in the U.S., making it the third branded fluticasone propionate nasal spray on the market. Innovus, based in San Diego, secured distribution through more than 10,000 independent pharmacies through AmerisourceBergen and McKesson and Walmart online.

As a second phase of its launch, Innovus Pharma will launch FlutiCare to large retail stores.

FlutiCare will be available OTC with the same prescription strength and same delivery method as Flonase and ClariSpray. The company currently believes that FlutiCare will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment. Innovus is also offering a monthly autoship plan.

“We are very excited to launch FlutiCare OTC and provide all patients with allergy relief,” stated Bassam Damaj, president and CEO Innovus Pharma. “FlutiCare traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1.”

FlutiCare becomes the company’s second available allergy relief product along with AllerVarx, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare and its upcoming saline nasal spray NasaVa.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES